A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours

BACKGROUND: The vascular disrupting agent ombrabulin shows synergy with docetaxel in vivo. Recommended phase II doses were determined in a dose escalation study in advanced solid tumours. METHODS: Ombrabulin (30-min infusion, day 1) followed by docetaxel (1-h infusion, day 2) every 3 weeks was explo...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Eskens, F A L M, Tresca, P, Tosi, D, Van Doorn, L, Fontaine, H, Van der Gaast, A, Veyrat-Follet, C, Oprea, C, Hospitel, M, Dieras, V
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group 2014
Assuntos:
Clinical Study
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4007230/
https://ncbi.nlm.nih.gov/pubmed/24714750
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2014.137
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares